基本信息
浏览量:7
职业迁徙
个人简介
I am the Director of the Molecular Biology and Technology Development at Praedicare, Inc. and an immunologist with extensive experience in in vitro cell-based assays and in vivo murine-based disease models. My research has focused on immune signaling and host-pathogen interactions, such as between Interferon Regulatory Factor 5 (IRF5) or Signal Transducer and Activator of Transcription 3 (STAT3) and gammaherpesvirus (HV) proteins. I am adept in a variety of cell-based assays, including apoptosis and proliferation assays, immunocytochemistry, cytokine induction, ELISA and other enzymatic assays, gene expression assays, and flow cytometry. I am also passionate about innovations and, for example, as a liaison in a joint venture with a startup, developed a graphene platform to deliver CRISPR components into specific cell types. I have specific training and expertise in creating antibody resources for research communities. At ATCC-BEI Resources, I won a CDC-BAA contract and was the Principal Investigator of “Engineering and Neutralizing Potential of SARS-CoV-2 Spike D614G Antibody Reagents”; wherein, I led an interdepartmental collaboration across Virology, Immunology, Mouse Studies, Protein Production, and Bioinformatic departments. We generated 33 hybridomas recognizing SARS-CoV-2 Spike/RBD proteins in various configurations: native and denatured conformations as a whole protein or as subunit segments. Potent neutralizing antibodies were generated and their Immunoglobulin variable (IgV) sequences were determined, benefiting antibody-based efforts against SARS-related infections. I also led a team of SMEs for sequencing and bioinformatics to determine the variable sequences of immunoglobulins (IgV) from M. tuberculosis hybridomas deposited in BEI. To satisfy high throughput demand to identify the Mtb hybridomas across various isotypes, we set up a new workflow using the high fidelity, Next Generation Sequencing method. Our effort has quadrupled the originally limited Mtb antibody IgV informatic resources. Herein, together with the SMEs of Praedicare Inc., with expertise in optimizing Mycobacterium TB drug regimens, we will exploit these Mtb antibodies in antibody-drug conjugates (ADC) to combat TB.
Leadership Qualifications: I have managed many projects involving multi-functional unit collaborations. I have managed PhD-, MS- or Bachelor- level research associates, and served as a liaison between Industry and academic collaborations. I have experience in delivering multiple research projects in which novel molecular- and cell-based assays were required and completed them on-budget and on-schedule. Many of my projects resulted in publications and led to awarded grants and contracts, including a Stony Brook Discovery Award, an SBIR phase I grant, an R01-STAT3 grant, NIAID MID-BRR option, and a CDC-BAA contract.
研究兴趣
论文共 10 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Hui-Chen Chang Foreman,Varvara Kirillov,Gabrielle Paniccia, Demetra Catalano, Trevor Andrunik, Swati Gupta,Laurie T Krug,Yue Zhang
H C Chang, T H Liao
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICSno. 2 (1990): 320-4
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn